Advertisement

Vitiligo pp 163-167 | Cite as

Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies

  • Katia Boniface
  • Julien SeneschalEmail author
Chapter

Abstract

The development of immunotherapies has remarkably improved the efficacy of treatment of patients with metastatic melanoma, as observed for example with immune checkpoint therapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death-1 (PD-1). Nonetheless, reinstatement of an effective antitumor immune response also contributes to the development of immune-related adverse events, including vitiligo-like depigmentation. This review aims to discuss special considerations in vitiligo-like lesions occurring in patients receiving anti-PD-1 therapies from a clinical and physiopathological perspective.

References

  1. 1.
    Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. J Hematol Oncol. 2017;10(1):88.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–67.PubMedCrossRefGoogle Scholar
  6. 6.
    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10(8):1338–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006;126(12):2658–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19(1):81–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Sibaud V, David I, Lamant L, Resseguier S, Radut R, Attal J, et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res. 2015;25(6):555–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22(16):4023–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–61.e1.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–12.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2017;44(2):117–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012;72(20):5209–18.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Byrne KT, Cote AL, Zhang P, Steinberg SM, Guo Y, Allie R, et al. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest. 2011;121(5):1797–809.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys. 2014;563:28–34.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12(9):406–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Kawakami Y, Suzuki Y, Shofuda T, Kiniwa Y, Inozume T, Dan K, et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res. 2000;13(Suppl 8):163–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996;184(6):2207–16.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000;192(11):1637–44.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Wolner ZJ, Marghoob AA, Pulitzer MP, Postow MA, Marchetti MA. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol. 2018;178:265.CrossRefGoogle Scholar
  28. 28.
    Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16(4):322–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Sandoval-Cruz M, Garcia-Carrasco M, Sanchez-Porras R, Mendoza-Pinto C, Jimenez-Hernandez M, Munguia-Realpozo P, et al. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10(12):762–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.1INSERM U1035, BMGIC, Immuno-dermatology teamUniversity of BordeauxBordeauxFrance
  2. 2.Department of Dermatology and Pediatric DermatologyNational Reference Center for Rare Skin Diseases, Saint-André Hospital, University of BordeauxBordeauxFrance

Personalised recommendations